Ideaya Biosciences Inc (IDYA)
$42.39
+0.1
(+0.24%)▲
Performance
- $42.31$44.11$42.39
0.19%
Downside
Day's Volatility :4.08%
Upside
3.9%
- $20.90$47.74$42.39
50.7%
Downside
52 Weeks Volatility :56.22%
Upside
11.21%
Returns
| Period | Ideaya Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 5.88% | 6.5% | 0.0% |
6 Months | 0.24% | 7.1% | 0.0% |
1 Year | 96.61% | 9.8% | 0.0% |
3 Years | 85.16% | 14.2% | -20.2% |
Highlights
Market Capitalization | 3.5B |
Book Value | $12.51 |
Earnings Per Share (EPS) | -2.0 |
Wall Street Target Price | 56.27 |
Profit Margin | 0.0% |
Operating Margin TTM | -1026.55% |
Return On Assets TTM | -15.0% |
Return On Equity TTM | -20.31% |
Revenue TTM | 15.5M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | -2.5% |
Gross Profit TTM | -38.6M |
EBITDA | -156.7M |
Diluted Eps TTM | -2.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.18 |
EPS Estimate Next Year | -2.56 |
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Next Quarter | -0.52 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 32.74%
Technicals Summary
Sell
Neutral
Buy
Ideaya Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ideaya Biosciences Inc | 21.24% | 0.24% | 96.61% | 85.16% | 524.67% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ideaya Biosciences Inc | NA | NA | NA | -2.18 | -0.2 | -0.15 | NA | 12.51 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ideaya Biosciences Inc | Buy | $3.5B | 524.67% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Ideaya Biosciences Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 8.03M → 3.92M (in $), with an average decrease of 51.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -27.44M → -39.57M (in $), with an average decrease of 20.1% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 101.3%
Institutional Holdings
FMR Inc
13.42%BlackRock Inc
7.88%Federated Hermes Inc
6.42%Vanguard Group Inc
5.49%T. Rowe Price Associates, Inc.
5.35%HHG PLC
5.03%
Corporate Announcements
Ideaya Biosciences Inc Earnings
Ideaya Biosciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.
Organization | Ideaya Biosciences Inc |
Employees | 124 |
CEO | Mr. Yujiro S. Hata |
Industry | Biotechnology |
